Loading
CareDx, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 29 Nov 2021.
CareDx, Inc.: what insiders have been doing
CareDx, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 88 filings came from 22 insiders.
No insider bought on the market over the period, while 6 insiders filed 20 sales totalling €8.8M. The totals do not cover 5 filings with an undisclosed amount. One trade stands out by size: a sale of €2.3M from Hanna John Walter JR, disclosed on 17 July 2026, or 0.094% of market capitalisation.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 88 filings in twelve months, the company is more active than the median of 19 filings across the 5,813 companies we follow on the same exchange. The full history, which starts in 2016, counts 2 purchases against 67 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 379.8 m USD and net income of -21.4 m USD.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
402
Thresholds
n/a
Buy Volume
€212,983
2 ops. · all time
Sell Volume
€15M
67 ops. · all time
Who traded when
BuySaleJohn Walter Hanna Jr.10 sales
Jeffrey Adam Novack9 sales
Valantine Hannah4 sales
Maag Peter3 sales
Christine Cournoyer2 sales
George Bickerstaff2 sales
+3 other insiders
Since the insiders bought
- -70.0%Entry US$43.14 · Close at T+365 US$12.95
- -72.2%Entry US$47.20 · Close at T+365 US$13.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate CareDx, Inc. Buy (bullish), based on 6 analysts. Average price target: US$61.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 12,353 of 24,148 companies
50.9
score / 100
Value37
Quality65
FCF yld1.1%
Earn yld-0.6%
EV/EBITDA·
ROE29%
Gross mgn68%
Net mgn-5.6%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$64.69
Analyst consensus
6 analystsBuy
US$46.00Target US$61.67(-5%)US$75.00
Income statement
RevenueUS$379.8M
Gross profitUS$256.6M68% margin
EBITDA-US$4.7M-1% margin
Net income-US$21.4M24.2% margin
Valuation
PER (trailing)30.8x
PER (forward)50.1x
P/Book7.8x
Beta2.38
Balance sheet & cash
Market capUS$3.3B
Total debtUS$26.2M
Free Cash FlowUS$35.4M
Debt / Equity5%
Profitability & ownership
ROE29.5%
ROA-0.3%
% insiders3.1%
% institutions104.1%
Last declaration on 5 October 2026
Declarations402 total
588 shares0Common StockSEC:0001366412-26-000008:0
997 shares@ US$66.230.0020% mcap5.2% of flowCommon StockSEC:0002019976-26-000011:0
3,018 shares@ US$66.230.0060% mcap21.5% of flowCommon StockSEC:0001543503-26-000007:0
8,511 shares@ US$66.230.017% mcap5.9% of flowCommon StockSEC:0001781127-26-000013:0
2,619 shares@ US$66.230.0052% mcap24.6% of flowCommon StockSEC:0002036499-26-000007:0
8,220 shares@ US$52.370.015% mcap57.6% of flowCommon StockSEC:0001543503-26-000006:0
6,688 shares@ US$52.370.012% mcap64.2% of flowCommon StockSEC:0002036499-26-000005:0
9,122 shares@ US$46.38140.015% mcap4.6% of flowCommonSEC144:0001950047-26-008202
7,000 shares@ US$45.30180.011% mcap3.5% of flowCommonSEC144:0001950047-26-008185
7,000 shares@ US$47.07220.012% mcap3.6% of flowCommonSEC144:0001950047-26-008069
7,000 shares@ US$46.89110.012% mcap3.6% of flowCommonSEC144:0001950047-26-007998
7,000 shares@ US$47.6930.012% mcap3.7% of flowCommonSEC144:0001950047-26-007990
4,200 shares@ US$47.73220.0070% mcap100.0% of flowCommonSEC144:0001950047-26-007860
6,902 shares@ US$47.660.012% mcap3.6% of flowCommonSEC144:0001950047-26-007920
27,332 shares@ US$45.82510.044% mcap13.8% of flowCommonSEC144:0001950047-26-007828
16,000 shares@ US$46.93580.026% mcap60.9% of flowCommon StockSEC:0001180466-26-000008:0
44,700 shares@ US$47.05810.074% mcap93.9% of flowCommon StockSEC:0001366412-26-000007:0
2,188 shares@ US$46.14920.0035% mcap8.3% of flowCommon StockSEC:0002019976-26-000010:0
500 shares@ US$46.750.0008% mcap1.9% of flowCommon StockSEC:0002019976-26-000010:1
20,000 shares@ US$46.2850.033% mcap23.7% of flowCommon StockSEC:0001329646-26-000003:0
2,688 shares@ US$47.090.0044% mcap100.0% of flowCommonSEC144:0001950047-26-007697
20,000 shares@ US$46.2850.033% mcap100.0% of flowCommonSEC144:0001950047-26-007676
46,963 shares@ US$46.39710.077% mcap24.0% of flowCommonSEC144:0001950047-26-007715
31,943 shares@ US$47.52660.053% mcap100.0% of flowCommonSEC144:0001950047-26-007655
16,000 shares@ US$47.090.027% mcap100.0% of flowCommonSEC144:0001958244-26-000483
25 of 402 declarations
About CareDx, Inc.
CareDx, Inc. (ticker: CDNA) is a U.S.-based precision medicine company listed on the NASDAQ in the United States, focused on improving outcomes for transplant patients. Its business model is built around transplant diagnostics, laboratory products, digital health tools, and patient support services. In practical terms, CareDx aims to provide clinicians, transplant centers, and patients with better visibility across the transplant journey, especially in the post-transplant monitoring phase. The company’s headquarters is in Brisbane, California, with additional primary operations in Omaha, Nebraska, and Stockholm, Sweden. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm?utm_source=openai))
Founded in 2000, CareDx has evolved from a diagnostics-focused company into a broader transplant solutions platform. Its commercially available testing portfolio includes AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare, and AlloSure Lung, which are used in monitoring kidney, heart, and lung transplant recipients. Beyond these molecular tests, the company offers digital health solutions and patient services designed to improve care coordination, workflow efficiency, and the patient experience. This integrated approach is important in a specialized market where clinical evidence, reimbursement, and physician adoption are key competitive drivers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, CareDx operates in a niche but strategically attractive segment of healthcare. The transplant monitoring market is shaped by the need for non-invasive, clinically validated tools and strong relationships with transplant centers. CareDx differentiates itself by combining molecular diagnostics with digital capabilities, rather than relying on a single-product model. Its geographic footprint is concentrated in North America and Europe through operations and commercial infrastructure, while its customer base spans transplant programs and healthcare stakeholders. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1217234/000121723426000018/cdna-20251231.htm?utm_source=openai))
Recent developments are notable for investors. CareDx reported full-year 2025 revenue of $380 million, up 14% year over year, supported by growth in testing services, patient and digital solutions, and product revenue. In April 2026, the company announced an agreement to sell the shares of its Swedish subsidiary CareDx AB and certain assets related to its kitted laboratory products business to Eurobio Scientific for $170 million in cash, suggesting a possible portfolio simplification and greater focus on core transplant diagnostics and digital offerings. For French-speaking investors, CDNA is therefore a U.S.-listed NASDAQ healthcare name with a specialized transplant franchise, a global operating footprint, and a recent strategic step that may reshape its business mix. ([investors.caredx.com](https://investors.caredx.com/news/news-details/2026/CareDx-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
